XERS - NASDAQ

Xeris Biopharma Holdings, Inc.

XERS·NASDAQ

$6.13

+2.1%

HealthcareBiotechnology

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.06B

EPS0.0035

P/E Ratio1750.51

Earnings Date08/06/2026

383.53M

Assets

19%

3Y+11.0%

5Y+141.0%

10Y+1044.0%

369.84M

Total Liabilities

3Y+24.0%

5Y+195.0%

10Y+465.0%

13.69M

Total Equity

-146%

3Y-70.0%

5Y-59.0%

10Y-143.0%

Xeris Biopharma Holdings, Inc. Funding & Solvency Profile

XERS · NASDAQ

Current Assets

Cash & Cash Equivalents111.04M

Net Receivables51.05M

Inventory68.67M

Other Current Assets9.55M

Total Current Assets240 M

Non-Current Assets

Property, Plant & Equipment27.06M

Goodwill & Intangible Assets110.94M

Long-Term Investments0.00

Other Non-Current Assets5.22M

Total Non-Current Assets32 M

Total Assets

383.53M

Financial Health Analysis

Current Ratio

2.19x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

27.02x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

131 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

63% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Xeris Biopharma Holdings, Inc. Balance Sheet

XERS • NASDAQ

Xeris Biopharma Holdings, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	111M	71.6M	67.4M	122M	67.3M	37.6M	19.5M	45.7M	42M	32.3M
Short-Term Investments	0.0	0.0	5M	0.0	35.2M	96.2M	56M	66.9M	0.0	0.0
Cash & Short-Term Investments	111M	71.6M	72.5M	122M	102.4M	133.8M	75.5M	112.6M	42M	32.3M
Net Receivables	51.1M	40.4M	39.2M	30.8M	17.5M	6.9M	4.7M	2.9M	1.2M	101K
Accounts Receivables	51.1M	40.4M	39.2M	30.8M	17.5M	6.9M	4.7M	0.0	1.2M	101K
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9M	0.0	0.0
Inventory	68.7M	48.2M	38.8M	24.7M	18.1M	8.4M	2.2M	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	4.6M	3.2M	5.1M	2.4M	809K	804K
Other Current Assets	9.5M	7.5M	5.8M	9.3M	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	240.3M	167.7M	156.3M	186.8M	142.6M	152.2M	87.5M	117.9M	44.1M	33.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	27.1M	28.2M	29.2M	9.5M	6.6M	6.7M	7.9M	2M	788K	312K
Goodwill	22.9M	22.9M	22.9M	22.9M	22.9M	0.0	0.0	0.0	0.0	0.0
Intangible Assets	88.1M	98.9M	109.8M	120.6M	131.5M	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	110.9M	121.8M	132.6M	143.5M	154.3M	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	4.1M	0.0	0.0	0.0	0.0	13.2M	0.0	0.0	0.0
Tax Assets	0.0	6.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	5.2M	-4.8M	4.5M	4.7M	829K	232K	420K	95K	157K	47K
Total Non-Current Assets	143.2M	155.4M	166.3M	157.7M	161.8M	6.9M	21.5M	2.1M	945K	359K
Total Assets	383.5M	323.1M	322.6M	344.5M	304.4M	159.2M	109M	120M	45M	33.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.1M	2.3M	11.6M	4.6M	8.9M	3.1M	5.6M	866K	2M	1.3M
Accounts Payable	3.1M	2.3M	11.6M	4.6M	8.9M	3.1M	5.6M	866K	2M	1.3M
Accrued Expenses	0.0	37.2M	28.7M	40.2M	44.5M	13.9M	12.7M	4.3M	1.6M	744K
Short Term Debt	6.2M	15.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	6.1M	3.5M	1.6M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	232K	234K	263K
Other Current Liabilities	100.3M	39.7M	51.4M	27.2M	25.6M	11.2M	9.1M	5M	1.3M	468K
Total Current Liabilities	109.6M	100.4M	95.2M	73.6M	79M	28.2M	27.3M	10.2M	4.9M	2.5M
NON-CURRENT LIABILITIES
Long Term Debt	31.5M	217M	190.9M	187.1M	88.1M	87M	58.3M	31.9M	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	2.3M	3.5M	4.9M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	228.7M	2M	6.2M	25.7M	37.1M	10.2M	8.9M	2.6M	98M	62.9M
Total Non-Current Liabilities	260.3M	252.2M	234.2M	225.7M	130.1M	97.2M	67.2M	34.5M	98M	62.9M
Capital Lease Obligations	0.0	39.3M	38.3M	11M	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	369.8M	352.7M	329.4M	299.3M	209.1M	125.4M	94.6M	44.6M	102.8M	65.5M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8M	-2.1M
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	97.9M	62.9M
Common Stock	17K	15K	14K	14K	13K	6K	3K	2K	1K	1K
Additional Paid-In Capital	0.0	642.3M	610.3M	600M	555.4M	371.1M	260.6M	196.1M	2.8M	2.1M
Retained Earnings	-671.3M	-671.9M	-617M	-554.8M	-460.1M	-337.4M	-246.2M	-120.7M	-60.6M	-34M
Accumulated Other Comprehensive Income/Loss	-25K	-25K	-25K	-23K	-31K	6K	43K	-52K	-440K	-268K
Other Total Stockholders' Equity	685M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-97.4M	-62.6M
Total Stockholders' Equity	13.7M	-29.6M	-6.8M	45.2M	95.2M	33.8M	14.4M	75.4M	-57.8M	-31.9M
Total Equity	13.7M	-29.6M	-6.8M	45.2M	95.2M	33.8M	14.4M	75.4M	-57.8M	-31.9M
SUMMARY
Total Liabilities & Equity	383.5M	323.1M	322.6M	344.5M	304.4M	159.2M	109M	120M	45M	33.5M
Total Investments	0.0	4.1M	5M	0.0	35.2M	96.2M	69.3M	66.9M	0.0	0.0
Total Debt	37.8M	271.4M	229.2M	198.1M	88.1M	87M	58.3M	31.9M	0.0	0.0
Net Debt	-73.3M	199.8M	161.7M	76.1M	20.8M	49.4M	38.8M	-13.8M	-42M	-32.3M
Shares Outstanding	165,924,000	165,924,000	165,924,000	165,924,000	165,924,000	165,924,000	165,924,000	165,924,000	165,924,000	165,924,000

SEC Filings

XERS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2025 N/A	April 23, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	April 21, 2026	April 20, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 02, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 27, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 08, 2026	January 08, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 01, 2025	December 01, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing

Showing 1 to 10 of 78 filings

Related Guides

Blog Categories

Continue your XERS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.